News
Discover the latest news from
ID SOLUTIONS
MEDICA 2024 : Meet the Experts from Bioshare Solutions
Meet Bioshare Solutions at MEDICA 2024.
ID SOLUTIONS Oncology at the SFMPP Congress
Meet ID SOLUTIONS Oncology & our partner Diatech Pharmacogenetics at the SFMPP !
Event : POLA WORKSHOP
Meet ID SOLUTIONS Oncology at the Oligodendroglioma workshop.
ASCO 2024 Congress: meet the ID SOLUTIONS Oncology team!
Meeting between oncology professionals and creating partnerships (…)
Liquid biopsy follow-up
Patients with advanced ER+/HER2- breast cancer treated with endocrine therapy are at greater risk of developing resistance mutations in various genes, including Estrogen Receptor 1 (ESR1).
February 4th – WORLD CANCER DAY
ID SOLUTIONS supports and encourages all initiatives in the fight against cancer.
Nos dernières études cliniques
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
